<DOC>
	<DOCNO>NCT01172509</DOCNO>
	<brief_summary>Our overall objective apply Transcranial Magnetic Stimulation ( TMS ) develop measure human synaptic plasticity brain excitatory : inhibitory ratio ( E : I ratio ) , propose novel biomarkers outcome measure expedite clinical trial treatment Autism Spectrum Disorder ( ASD ) . One potential therapeutic agent , R-baclofen investigate protocol . TMS safe , inexpensive noninvasive mean focally stimulate human brain . Presently , TMS extensive use mean measure regional brain excitability , dependent local synaptic strength . TMS use temporarily alter synaptic strength well acutely measure level cortical excitability short long interval inhibition . Since alter synaptic plasticity imbalanced inhibitory : excitatory ratio cite fundamental abnormality ASD , hypothesize severity ASD-related learn deficit improvement therapy correlate TMS measure synaptic plasticity E : I ratio . We propose embed TMS measure synaptic plasticity E : I ratio 'Proof Principal ' trial R-baclofen examine : Aim 1 : Whether R-baclofen ( potential therapeutic agent ASD ) predictably alters TMS measure synaptic plasticity E : I ratio function plasma concentration adult volunteer . We test follow hypothesis : 1 . R-baclofen produce significant change TMS measure LTD E : I ratio ; 2 . R-baclofen plasma level TMS measure LTD E : I ratio show predictable exposure-response relationship . Exploratory Aim 1 : Whether presence genetic polymorphism BDNF GABA-B receptor gene moderate effect TMS measure R-baclofen effect . We test follow hypothesis : 1 . Presence BDNF val66met allele associate decreased long-term depression ( LTD ) cortical excitability 2 . Polymorphisms GABA-B receptor gene associate altered magnitude response R-baclofen measure TMS</brief_summary>
	<brief_title>TMS Measures Plasticity Excitatory/Inhibitory Ratio Biomarkers : R-baclofen Effects Normal Volunteers</brief_title>
	<detailed_description>The design double-blind placebo control 5 way crossover trial single dose placebo x 2 ( 0 mg ) , 3 , 10 , 25 mg R-baclofen follow plasma level 0 , 30 , 60 , 90 , 140 minute dose ; TMS test 0 , 30 , 60 , 90 ( cTBS application 90 minute time point ) , 95 , periodically every 5-10 minute MEPs return baseline . There total 7 visit . Patients come screen visit , schedule return 1 baseline visit ( cTBS without drug ) 5 crossover visit . At crossover visit venous line place blood sample single dose study drug one five dose level give orally time 0 . There one-week washout crossover arm ( R-baclofen mean Tmax approximately 80 minute terminal half life 4.9 hour ) .</detailed_description>
	<criteria>Age : 1830 IQ : high 85 Normal physical examination Exclusion Criteria significant medical problem ongoing medication All female participant require negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>plasticity</keyword>
	<keyword>excitatory</keyword>
	<keyword>inhibitory</keyword>
	<keyword>synaptic plasticity</keyword>
	<keyword>R-Baclofen</keyword>
	<keyword>TMS</keyword>
	<keyword>transcranial magnetic stimulation</keyword>
	<keyword>biomarker</keyword>
	<keyword>autism</keyword>
</DOC>